Literature DB >> 19076442

Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

H Diana Rosas1, David H Salat, Stephanie Y Lee, Alexandra K Zaleta, Nathanael Hevelone, Steven M Hersch.   

Abstract

Significant advances are being made in our understanding of basic pathophyiological and biochemical mechanisms that cause Huntington's disease (HD). There is increasing reason to believe that pathologic alterations occur in the brain for years before symptoms manifest. The "classic" hallmark of neuropathology in HD is selective neurodegeneration in which vulnerable populations of neurons degenerate while less vulnerable populations are spared. While the earliest and most striking neuropathologic changes have been found in the neostriatum, neuronal loss has been identified in many other regions of the brain. We report topologically selective, early, and progressive changes in the cortex, striatum, extrastriatal brain structures, and white matter throughout the spectrum of disease. Our growing understanding of HD underscores the reality that points to the complexity of HD. A single, well-defined, genetic mutation causes a cascade of events whose final result is an aggregate insult of the homeostatic process. We explore possible explanations for the selective vulnerability of the brain in HD. The ultimate goal in HD is to develop disease-modifying therapies that will prevent the onset of clinical symptoms in those individuals who are at risk and slow the progression of symptoms in those individuals already affected with symptoms. Understanding changes in brain morphometry and their relationship to clinical symptoms may provide important and new insights into basic pathophysiological mechanisms at play in the disease.

Entities:  

Mesh:

Year:  2008        PMID: 19076442      PMCID: PMC2813569          DOI: 10.1196/annals.1427.034

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  83 in total

1.  Quantitative neuropathological changes in presymptomatic Huntington's disease.

Authors:  E Gómez-Tortosa; M E MacDonald; J C Friend; S A Taylor; L J Weiler; L A Cupples; J Srinidhi; J F Gusella; E D Bird; J P Vonsattel; R H Myers
Journal:  Ann Neurol       Date:  2001-01       Impact factor: 10.422

Review 2.  Loss of normal huntingtin function: new developments in Huntington's disease research.

Authors:  E Cattaneo; D Rigamonti; D Goffredo; C Zuccato; F Squitieri; S Sipione
Journal:  Trends Neurosci       Date:  2001-03       Impact factor: 13.837

3.  Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats.

Authors:  M F Perutz; A H Windle
Journal:  Nature       Date:  2001-07-12       Impact factor: 49.962

4.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

5.  Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity.

Authors:  N R Jana; M Tanaka; G h Wang; N Nukina
Journal:  Hum Mol Genet       Date:  2000-08-12       Impact factor: 6.150

6.  Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation.

Authors:  K P Murphy; R J Carter; L A Lione; L Mangiarini; A Mahal; G P Bates; S B Dunnett; A J Morton
Journal:  J Neurosci       Date:  2000-07-01       Impact factor: 6.167

7.  Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits.

Authors:  A D Lawrence; L H Watkins; B J Sahakian; J R Hodges; T W Robbins
Journal:  Brain       Date:  2000-07       Impact factor: 13.501

8.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.

Authors:  S E Andrew; Y P Goldberg; B Kremer; H Telenius; J Theilmann; S Adam; E Starr; F Squitieri; B Lin; M A Kalchman
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

9.  Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.

Authors:  M F Beal; W R Matson; E Storey; P Milbury; E A Ryan; T Ogawa; E D Bird
Journal:  J Neurol Sci       Date:  1992-03       Impact factor: 3.181

10.  Regional and cellular gene expression changes in human Huntington's disease brain.

Authors:  Angela Hodges; Andrew D Strand; Aaron K Aragaki; Alexandre Kuhn; Thierry Sengstag; Gareth Hughes; Lyn A Elliston; Cathy Hartog; Darlene R Goldstein; Doris Thu; Zane R Hollingsworth; Francois Collin; Beth Synek; Peter A Holmans; Anne B Young; Nancy S Wexler; Mauro Delorenzi; Charles Kooperberg; Sarah J Augood; Richard L M Faull; James M Olson; Lesley Jones; Ruth Luthi-Carter
Journal:  Hum Mol Genet       Date:  2006-02-08       Impact factor: 6.150

View more
  22 in total

1.  Stability of resting fMRI interregional correlations analyzed in subject-native space: a one-year longitudinal study in healthy adults and premanifest Huntington's disease.

Authors:  Tyler M Seibert; D S Adnan Majid; Adam R Aron; Jody Corey-Bloom; James B Brewer
Journal:  Neuroimage       Date:  2011-09-10       Impact factor: 6.556

2.  Moving toward a gene therapy for Huntington's disease.

Authors:  J C Glorioso; J B Cohen; D L Carlisle; I Munoz-Sanjuan; R M Friedlander
Journal:  Gene Ther       Date:  2015-12       Impact factor: 5.250

Review 3.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 4.  Gene therapy in mouse models of huntington disease.

Authors:  Amber L Southwell; Paul H Patterson
Journal:  Neuroscientist       Date:  2011-04       Impact factor: 7.519

5.  Alterations in brain transition metals in Huntington disease: an evolving and intricate story.

Authors:  H Diana Rosas; Y Iris Chen; Gheorghe Doros; David H Salat; Nan-kuei Chen; Ken K Kwong; Ashley Bush; Jonathan Fox; Steven M Hersch
Journal:  Arch Neurol       Date:  2012-07

6.  Comparison of vertical and horizontal saccade measures and their relation to gray matter changes in premanifest and manifest Huntington disease.

Authors:  Jason Rupp; Mario Dzemidzic; Tanya Blekher; John West; Siu Hui; Joanne Wojcieszek; Andrew J Saykin; David A Kareken; Tatiana Foroud
Journal:  J Neurol       Date:  2011-08-18       Impact factor: 4.849

7.  microRNAs in CNS disorders.

Authors:  Jannet Kocerha; Sakari Kauppinen; Claes Wahlestedt
Journal:  Neuromolecular Med       Date:  2009-06-18       Impact factor: 3.843

Review 8.  Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

Authors:  Robert Schwarcz; Paolo Guidetti; Korrapati V Sathyasaikumar; Paul J Muchowski
Journal:  Prog Neurobiol       Date:  2009-04-24       Impact factor: 11.685

9.  Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection".

Authors:  H Diana Rosas; Stephanie Y Lee; Alexander C Bender; Alexandra K Zaleta; Mark Vangel; Peng Yu; Bruce Fischl; Vasanth Pappu; Christina Onorato; Jang-Ho Cha; David H Salat; Steven M Hersch
Journal:  Neuroimage       Date:  2009-10-19       Impact factor: 6.556

10.  Metabolic network as a progression biomarker of premanifest Huntington's disease.

Authors:  Chris C Tang; Andrew Feigin; Yilong Ma; Christian Habeck; Jane S Paulsen; Klaus L Leenders; Laura K Teune; Joost C H van Oostrom; Mark Guttman; Vijay Dhawan; David Eidelberg
Journal:  J Clin Invest       Date:  2013-08-29       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.